RPS6KA1 and type 2 diabetes mellitus: In murine models of T2D, RPS6KA1 has been implicated in impaired glucose homeostasis in β-pancreatic, muscle and liver cells [40,41], which is improved upon sitagliptin (DPP-4 inhibitor; antidiabetic drug) administration [42].